Alectinib is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.

Lenvatinib mesylate is a synthetic, orally available inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity.

Gefitinib hydrochloride is a selective tyrosine kinase receptor inhibitor.

Apatinib mesylate is an orally bioavailable, selective VEGFR2 inhibitor.

Regorafenib is an oral multi-kinase inhibitor, and Cytochrome P450 2C9 Inhibitor.

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity.

Pazopanib hydrochloride is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity.

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor.